Stem definition | Drug id | CAS RN |
---|---|---|
2657 | 55142-85-3 |
Dose | Unit | Route |
---|---|---|
0.50 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0.50 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 15.81 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 80 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
Oct. 31, 1991 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug interaction | 63.21 | 32.43 | 46 | 1249 | 209709 | 56081063 |
Sopor | 51.45 | 32.43 | 19 | 1276 | 20903 | 56269869 |
Hyponatraemic syndrome | 43.72 | 32.43 | 8 | 1287 | 536 | 56290236 |
Hyperkalaemia | 40.96 | 32.43 | 21 | 1274 | 50844 | 56239928 |
Hypochloraemia | 39.96 | 32.43 | 9 | 1286 | 1703 | 56289069 |
Apraxia | 39.92 | 32.43 | 9 | 1286 | 1710 | 56289062 |
Hypercreatininaemia | 39.59 | 32.43 | 7 | 1288 | 386 | 56290386 |
Cerebral haemorrhage | 35.81 | 32.43 | 16 | 1279 | 28590 | 56262182 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug interaction | 56.14 | 27.06 | 57 | 1366 | 208486 | 31487435 |
Sopor | 50.06 | 27.06 | 19 | 1404 | 11533 | 31684388 |
Slow speech | 49.03 | 27.06 | 11 | 1412 | 1043 | 31694878 |
Intentional self-injury | 43.99 | 27.06 | 18 | 1405 | 13297 | 31682624 |
Alcohol interaction | 38.40 | 27.06 | 11 | 1412 | 2778 | 31693143 |
Melaena | 36.50 | 27.06 | 21 | 1402 | 32633 | 31663288 |
Electrocardiogram QT prolonged | 31.06 | 27.06 | 20 | 1403 | 37967 | 31657954 |
Hyponatraemia | 31.06 | 27.06 | 26 | 1397 | 73773 | 31622148 |
Mechanical urticaria | 30.51 | 27.06 | 5 | 1418 | 87 | 31695834 |
Anaemia | 30.01 | 27.06 | 42 | 1381 | 213480 | 31482441 |
Drug abuse | 29.10 | 27.06 | 27 | 1396 | 87731 | 31608190 |
Coombs negative haemolytic anaemia | 27.90 | 27.06 | 5 | 1418 | 150 | 31695771 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug interaction | 105.46 | 24.66 | 102 | 2831 | 381339 | 70544172 |
Sopor | 91.99 | 24.66 | 38 | 2895 | 31229 | 70894282 |
Melaena | 62.34 | 24.66 | 35 | 2898 | 56320 | 70869191 |
Intentional self-injury | 56.14 | 24.66 | 27 | 2906 | 31623 | 70893888 |
Anaemia | 51.99 | 24.66 | 73 | 2860 | 403350 | 70522161 |
Cerebral haemorrhage | 50.37 | 24.66 | 30 | 2903 | 53834 | 70871677 |
Hyponatraemic syndrome | 47.64 | 24.66 | 10 | 2923 | 753 | 70924758 |
Hyponatraemia | 44.31 | 24.66 | 43 | 2890 | 160044 | 70765467 |
Hyperkalaemia | 42.09 | 24.66 | 35 | 2898 | 106556 | 70818955 |
Slow speech | 41.90 | 24.66 | 11 | 2922 | 2181 | 70923330 |
Drug abuse | 41.58 | 24.66 | 40 | 2893 | 147216 | 70778295 |
Alcohol interaction | 33.72 | 24.66 | 11 | 2922 | 4642 | 70920869 |
Hypertensive crisis | 32.84 | 24.66 | 16 | 2917 | 19246 | 70906265 |
Hypochloraemia | 32.66 | 24.66 | 9 | 2924 | 2142 | 70923369 |
Apraxia | 30.69 | 24.66 | 9 | 2924 | 2674 | 70922837 |
Electrocardiogram QT prolonged | 30.03 | 24.66 | 26 | 2907 | 83491 | 70842020 |
Hypoglycaemia | 29.22 | 24.66 | 27 | 2906 | 94337 | 70831174 |
Rectal haemorrhage | 26.76 | 24.66 | 22 | 2911 | 65809 | 70859702 |
Subdural haematoma | 26.54 | 24.66 | 16 | 2917 | 29282 | 70896229 |
Hypercreatininaemia | 24.96 | 24.66 | 6 | 2927 | 833 | 70924678 |
Haematidrosis | 24.87 | 24.66 | 4 | 2929 | 67 | 70925444 |
None
Source | Code | Description |
---|---|---|
ATC | B01AC05 | BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS Platelet aggregation inhibitors excl. heparin |
FDA PE | N0000008832 | Decreased Platelet Aggregation |
FDA EPC | N0000175578 | Platelet Aggregation Inhibitor |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D065689 | Cytochrome P-450 CYP2C19 Inhibitors |
MeSH PA | D065607 | Cytochrome P-450 Enzyme Inhibitors |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D005343 | Fibrinolytic Agents |
MeSH PA | D006401 | Hematologic Agents |
MeSH PA | D065606 | Metabolic Side Effects of Drugs and Substances |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D010975 | Platelet Aggregation Inhibitors |
MeSH PA | D058914 | Purinergic Antagonists |
MeSH PA | D058919 | Purinergic P2 Receptor Antagonists |
MeSH PA | D058921 | Purinergic P2Y Receptor Antagonists |
CHEBI has role | CHEBI:48676 | fibrin modulating agent |
CHEBI has role | CHEBI:50248 | hematologic agents |
CHEBI has role | CHEBI:50249 | anticoagulants |
CHEBI has role | CHEBI:50427 | platelet aggregation inhibitors |
CHEBI has role | CHEBI:68563 | ADP receptor subtype P2Y12 antagonists |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Percutaneous coronary intervention | indication | 415070008 | |
Cerebrovascular Occlusion | indication | ||
Subacute Stent Thrombosis Prevention | indication | ||
Prevention of Cerebral Thrombosis | indication | ||
Obstruction of bile duct | contraindication | 30144000 | |
Gastrointestinal ulcer | contraindication | 40845000 | |
Hyperlipidemia | contraindication | 55822004 | DOID:1168 |
Acute nephropathy | contraindication | 58574008 | |
Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
Gastrointestinal hemorrhage | contraindication | 74474003 | |
Ascorbic acid deficiency | contraindication | 76169001 | |
Thrombotic thrombocytopenic purpura | contraindication | 78129009 | DOID:10772 |
Congenital hypoplastic anemia | contraindication | 88854002 | DOID:1339 |
Leukemia, disease | contraindication | 93143009 | DOID:1240 |
Procedure on central nervous system | contraindication | 118679007 | |
Bleeding | contraindication | 131148009 | |
Arterial aneurysm | contraindication | 233981004 | |
Cerebral hemorrhage | contraindication | 274100004 | |
Lumbar puncture | contraindication | 277762005 | |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
Surgical procedure | contraindication | 387713003 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 7.18 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
P2Y purinoceptor 12 | GPCR | ANTAGONIST | WOMBAT-PK | CHEMBL | |||||
Prostaglandin G/H synthase 1 | Enzyme | IC50 | 4.28 | WOMBAT-PK | |||||
Alpha-2A adrenergic receptor | GPCR | Ki | 6.85 | DRUG MATRIX | |||||
Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 6.75 | DRUG MATRIX | |||||
Alpha-2B adrenergic receptor | GPCR | Ki | 6.86 | DRUG MATRIX | |||||
Alpha-2C adrenergic receptor | GPCR | Ki | 6.77 | DRUG MATRIX | |||||
Cytochrome P450 2D6 | Enzyme | IC50 | 5.20 | DRUG MATRIX | |||||
Cytochrome P450 2A6 | Enzyme | Ki | 6.70 | WOMBAT-PK | |||||
Bile salt export pump | Transporter | IC50 | 4.13 | CHEMBL | |||||
Cytochrome P450 2C19 | Enzyme | IC50 | 6.18 | DRUG MATRIX | |||||
Cytochrome P450 2B6 | Enzyme | INHIBITOR | IC50 | 6.70 | IUPHAR | ||||
Prostaglandin G/H synthase 2 | Enzyme | IC50 | 4.33 | WOMBAT-PK | |||||
Membrane-associated progesterone receptor component 1 | Membrane receptor | Ki | 5.70 | DRUG MATRIX | |||||
Bile salt export pump | Transporter | IC50 | 4.31 | CHEMBL |
ID | Source |
---|---|
4020513 | VUID |
N0000148235 | NUI |
D01028 | KEGG_DRUG |
53885-35-1 | SECONDARY_CAS_RN |
4020458 | VANDF |
4020513 | VANDF |
C0040207 | UMLSCUI |
CHEBI:9588 | CHEBI |
TIC | PDB_CHEM_ID |
CHEMBL833 | ChEMBL_ID |
DB00208 | DRUGBANK_ID |
CHEMBL1717 | ChEMBL_ID |
D013988 | MESH_DESCRIPTOR_UI |
5472 | PUBCHEM_CID |
7307 | IUPHAR_LIGAND_ID |
3908 | INN_ID |
OM90ZUW7M1 | UNII |
10594 | RXNORM |
2177 | MMSL |
31069 | MMSL |
5582 | MMSL |
d00514 | MMSL |
003610 | NDDF |
003611 | NDDF |
108971003 | SNOMEDCT_US |
386950000 | SNOMEDCT_US |
395904008 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Ticlopidine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-0079 | TABLET, FILM COATED | 250 mg | ORAL | ANDA | 25 sections |